Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma

BACKGROUND: Sunitinib is a tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma (RCC). Few data evaluated severe buccodental adverse events. The aim of this study was to evaluate sunitinib buccodental toxicity in patients with metastatic RCC and to compare it with that of sta...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Gilabert, M, Provansal, M, Cappiello, M, Walz, Y, Salem, N, Tarpin, C, Brunelle, S, Thomassin, J, Gravis, G
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2013
Gaiak:
Clinical Study
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3790170/
https://ncbi.nlm.nih.gov/pubmed/24045668
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.516
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak